104 related articles for article (PubMed ID: 9582586)
1. Urinary pharmacodynamics of low-dose ciprofloxacin and ofloxacin.
Stein GE; Schooley S; McMillan J
Diagn Microbiol Infect Dis; 1998 Apr; 30(4):261-5. PubMed ID: 9582586
[TBL] [Abstract][Full Text] [Related]
2. [Antibacterial activity of ofloxacin in urine for 4 days after a single oral dose of 400 mg].
Guibert J; Kitzis MD; Acar JF
Pathol Biol (Paris); 1998 Oct; 46(8):656-60. PubMed ID: 9871938
[TBL] [Abstract][Full Text] [Related]
3. Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.
Hofbauer H; Naber KG; Kinzig-Schippers M; Sörgel F; Rustige-Wiedemann C; Wiedemann B; Reiz A; Kresken M
Infection; 1997; 25(2):121-6. PubMed ID: 9108190
[TBL] [Abstract][Full Text] [Related]
4. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
Well M; Naber KG; Kinzig-Schippers M; Sörgel F
Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.
Naber KG; Theuretzbacher U; Moneva-Koucheva G; Stass H
Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):783-9. PubMed ID: 10614952
[TBL] [Abstract][Full Text] [Related]
6. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
[TBL] [Abstract][Full Text] [Related]
7. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Stein GE; Schooley S
Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
[TBL] [Abstract][Full Text] [Related]
8. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers.
Naber CK; Hammer M; Kinzig-Schippers M; Sauber C; Sörgel F; Bygate EA; Fairless AJ; Machka K; Naber KG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3524-30. PubMed ID: 11709334
[TBL] [Abstract][Full Text] [Related]
9. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin.
Echols R; Weinstein MP; O'Keeffe B; Shah A; Heller AH
J Antimicrob Chemother; 1994 Jan; 33(1):111-8. PubMed ID: 8157551
[TBL] [Abstract][Full Text] [Related]
10. [Antibacterial activity of urine after administration of ofloxacin for 5 days].
Drugeon H; Veyries ML; Levacher M; Garnier M; Aymard G; Giroud JP; Rouveix B
Therapie; 2000; 55(6):691-7. PubMed ID: 11234464
[TBL] [Abstract][Full Text] [Related]
11. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG
Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.
Zeiler HJ; Beermann D; Wingender W; Förster D; Schacht P
Infection; 1988; 16 Suppl 1():S19-23. PubMed ID: 3286510
[TBL] [Abstract][Full Text] [Related]
13. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.
Wagenlehner FM; Wydra S; Onda H; Kinzig-Schippers M; Sörgel F; Naber KG
Antimicrob Agents Chemother; 2003 Dec; 47(12):3789-94. PubMed ID: 14638484
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.
Israel D; Gillum JG; Turik M; Harvey K; Ford J; Dalton H; Towle M; Echols R; Heller AH; Polk R
Antimicrob Agents Chemother; 1993 Oct; 37(10):2193-9. PubMed ID: 8257144
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Lister PD; Sanders CC
Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
[TBL] [Abstract][Full Text] [Related]
17. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli.
Stein GE; Schooley SL; Nicolau DP
Int J Antimicrob Agents; 2008 Oct; 32(4):320-5. PubMed ID: 18715762
[TBL] [Abstract][Full Text] [Related]
18. [Antibacterial activity of ciprofloxacin in the urine during four days after a single 500 mg and 750 mg oral dose].
Guibert J; Kitzis MD; Acar JF
Pathol Biol (Paris); 1994 Jun; 42(6):587-92. PubMed ID: 7854859
[TBL] [Abstract][Full Text] [Related]
19. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
